CellGenix Appoints Dr. Udo Nirenberg as Vice President Quality Management and Member of the Management Team
CellGenix, a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, is pleased to announce the appointment of Dr. Udo Nirenberg as Vice President of Quality Management and member of the management team.
Dr. Udo Nirenberg joined CellGenix in early 2018 as Head of Quality Management where he is responsible for quality control, quality assurance and regulatory affairs. He will now represent these important areas in the management team and contribute to further advancing the high quality of the CellGenix product portfolio. The management team is completed by Prof. Dr. med. Felicia M. Rosenthal (Chief Executive Officer), Frank Hecht (Vice President Marketing & Sales) and Dr. Bernd Leistler (Vice President Development & Production).
"We are delighted to welcome Dr. Nirenberg in our management team," said Prof. Felicia Rosenthal. "Udo is an enormously talented executive with a truly global perspective and a proven track record. He brings the leadership credentials and experience to move all quality aspects of the company forward, advancing our strong position as one of the world leaders in the development and supply of high quality raw materials for cell and gene therapy manufacturing."
"I am very excited to join the management team of CellGenix", said Dr. Udo Nirenberg. "I will share my knowledge and experience in quality management to continuously improve the quality system in order to supply our customers with high quality raw materials for cell and gene therapy manufacturing"
In 1988, Udo Nirenberg started his career as Head of Quality Control at Bachem AG in Switzerland, a leading manufacturer of peptides. In the following years he took over the responsibility for quality control, quality assurance and regulatory affairs departments at Bachem affiliates in the United States. Prior to his position at CellGenix, Dr. Nirenberg was responsible for quality control testing of biopharmaceuticals and quality management for more than 10 years at Solvias AG, a globally acting analytical contract laboratory in Switzerland. He holds a degree in chemistry and received his Ph.D. in analytical chemistry from the University of Frankfurt/Main, Germany.
CellGenix is a leading manufacturer and developer of premium-grade reagents for clinical cell culture needs. The company has more than two decades of in-house expertise in GMP manufacturing and development of products in the field of cell therapy, gene therapy and regenerative medicine. The superior quality GMP reagents are used by leading experts and are proven in clinical trials and commercial manufacturing throughout the world. CellGenix is headquartered in Freiburg, Germany and operates a subsidiary in Portsmouth, New Hampshire, USA, serving the North American market.
CellGenix GmbH Prof. Dr. med. Felicia M. Rosenthal Chief Executive Officer T.:+49 761 88889100 E.:firstname.lastname@example.org www.cellgenix.com End of Media Release Issuer: CellGenix GmbH Key word(s): Research/Technology
05.11.2018 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de